Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Dsk2 UBA domain, (agarose immobilized)

BML-UW9835-0500 0.5 ml 340.00 USD
Do you need bulk/larger quantities?

Product Specification

Sequence:Peptide corresponding to the amino acid sequence of Dsk2 residues 327-371.
Source:Synthetic. UBA (residues 327-371) of Dsk2 protein immobilized on agarose.
UniProt ID:P48510
Concentration:≥2 mg peptide per ml of settled resin
Formulation:50% slurry. In 0.1M TRIS-HCl, pH 8.0 containing 0.5M NaCl and 0.09% sodium azide.
Quality Control:Western blot analysis of denatured eluents detects polyubiquitin conjugates when ubiquitin chains are bound.
Shipping:Blue Ice Not Frozen
Long Term Storage:+4°C
Scientific Background:Dsk2p from Saccharomyces cerevisiae belongs to a class of proteins that contain a ubiquitin-like (UbL) domain at the N-terminus together with a ubiquitin-associated (UBA) domain at the C-terminus. It has been shown that the C-terminal UBA domain of Dsk2p binds to K48-linked polyubiquitin chains and that the N-terminal Ubl domain of Dsk2p interacts with the proteasome. The Dsk2 UBA domain may therefore be particularly useful for capturing the totality of ubiquitin-modified proteins from complex protein mixtures.
UBA-agarose binding of K48- and K63-linked ubiquitin chains after SDS-PAGE followed by blotting onto PVDF and probing with a ubiquitin chainreactive antibody (Prod. No. BML-PW8805). Antibody dilution 1:1000 using ECL procedure. Lane 1: MW markers; Lane 2: Multi ubiquitin chains (Ub2-7, K48-linked) (Prod. No. BML-UW8860); Lane 3: Bound; Lane 4: Unbound; Lane 5: Multi ubiquitin chains (Ub2-7, K63-linked) (Prod. No. BML-UW9570); Lane 6: Bound; Lane 7: Unbound.
Please mouse over

Related Literature

Stem Cells
Stem Cells
Download as PDF

Ubiquitin & UBL Signaling Catalog
Ubiquitin & UBL Signaling Catalog
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,